Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: Mechanism of drug recognition and resistance

Zhigang Liu, Ravikiran S. Yedidi, Yong Wang, Tamaria G. Dewdney, Samuel J. Reiter, Joseph S Brunzelle, Iulia A. Kovari, Ladislau C. Kovari*

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Lopinavir (LPV) is a second generation HIV-1 protease inhibitor. Drug resistance has rapidly emerged against LPV since its US FDA approval on September 15, 2000. Mutations at residues 32I, L33F, 46I, 47A, I54V, V82A, I84V, and L90M render the protease drug resistant against LPV. We report the crystal structure of a clinical isolate multi-drug resistant (MDR) 769 HIV-1 protease (resistant mutations at residues 10, 36, 46, 54, 62, 63, 71, 82, 84, and 90) complexed with LPV and the in vitro enzymatic IC50 of LPV against MDR 769. The structural and functional studies demonstrate significant drug resistance of MDR 769 against LPV, arising from reduced interactions between LPV and the protease target.

Original languageEnglish (US)
Pages (from-to)199-204
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume437
Issue number2
DOIs
StatePublished - Jul 26 2013

Keywords

  • HIV-1 protease
  • IC50
  • Lopinavir
  • Multi-drug resistance
  • X-ray crystallography

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: Mechanism of drug recognition and resistance'. Together they form a unique fingerprint.

  • Cite this